• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Nakamoto Holdings to Participate in ICR Conference Spotlight Series

    6/17/25 4:05:00 PM ET
    $NAKA
    $UPXI
    Medical/Nursing Services
    Health Care
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $NAKA alert in real time by email

    Nakamoto Holdings Inc. ("Nakamoto"), a Bitcoin-native holding that has entered into a definitive merger agreement with KindlyMD, Inc. (NASDAQ:NAKA) ("KindlyMD"), is pleased to share that David Bailey, Chief Executive Officer, will participate in an ICR Conference Spotlight Series webinar taking place on Friday, June 20, 2025 at 11am ET.

    The webinar, titled "HODL On Tight: Examining The Rise of Public Market Crypto Balance Sheet Strategies", will examine the evolution of crypto balance sheet strategies and the strategic rationale and benefits driving the proliferation of these public market companies. David will be joined by executives from Clear Street Investment Banking, Upexi, Inc. (NASDAQ:UPXI), and Sol Strategies, Inc. (CSE:HODL).

    To learn more about the event please click here.

    About Nakamoto

    Nakamoto is a Bitcoin treasury company building a global portfolio of Bitcoin-native companies. Nakamoto plans to establish the first publicly traded conglomerate of Bitcoin companies by accumulating Bitcoin in its treasury and by leveraging its treasury to acquire and develop an ecosystem of Bitcoin companies across finance, media, advisory and more. The company aims to provide commercial and financial infrastructure for the next generation of capital markets. For more information, please visit www.nakamoto.com.

    Forward-Looking Statements

    All statements, other than statements of historical fact, included in this release that address activities, events or developments that Kindly MD or Nakamoto expects, believes or anticipates will or may occur in the future are forward-looking statements. Words such as "estimate," "project," "predict," "believe," "expect," "anticipate," "potential," "create," "intend," "could," "would," "may," "plan," "will," "guidance," "look," "goal," "future," "build," "focus," "continue," "strive," "allow" or the negative of such terms or other variations thereof and words and terms of similar substance used in connection with any discussion of future plans, actions, or events identify forward-looking statements. However, the absence of these words does not mean that the statements are not forward-looking. These forward-looking statements include, but are not limited to, statements regarding the proposed merger and related transactions, (collectively, the "Transactions") the expected closing of the proposed Transactions and the timing thereof and as adjusted descriptions of the post-transaction company and its operations, strategies and plans, integration, debt levels and leverage ratio, capital expenditures, cash flows and anticipated uses thereof, synergies, opportunities and anticipated future performance, including the management team and board of directors of the combined company and expected use of proceeds from the Transactions, and any post-closing transactions contemplated between the combined company and BTC Inc (and/or UTXO, LLC through BTC Inc). Information adjusted for the proposed Transactions should not be considered a forecast of future results. There are a number of risks and uncertainties that could cause actual results to differ materially from the forward-looking statements included in this release. These include the risk that Kindly MD and Nakamoto businesses (which may include the businesses of BTC Inc and/or UTXO in the future, as applicable) will not be integrated successfully and the risk that Kindly MD or the applicable governing bodies of BTC Inc and/or UTXO may not pursue or approve the terms of an acquisition of BTC Inc and/or UTXO; the risk that cost savings, synergies and growth from the proposed transaction may not be fully realized or may take longer to realize than expected; the possibility that shareholders of Kindly MD may not approve the issuance of new shares of Kindly MD common stock in the Transactions or that shareholders of Kindly MD may not approve the Transactions; the risk that a condition to closing of the Transactions may not be satisfied, that either party may terminate the merger agreement, the subscription agreements of the convertible debt purchase agreement or that the closing of the Transactions might be delayed or not occur at all; potential adverse reactions or changes to business or employee relationships, including those resulting from the announcement or completion of the Transactions; the parties do not receive regulatory approval of the Transactions; the occurrence of any other event, change, or other circumstances that could give rise to the termination of the merger agreement relating to the Transactions; the risk that changes in Kindly MD's capital structure and governance could have adverse effects on the market value of its securities; the ability of Kindly MD and Nakamoto to retain customers and retain and hire key personnel and maintain relationships with their suppliers and customers and on Kindly MD and Nakamoto's operating results and business generally; the risk the Transactions could distract management from ongoing business operations or cause Kindly MD and/or Nakamoto to incur substantial costs; the risk that Kindly MD may be unable to reduce expenses or access financing or liquidity; the impact of any related economic downturn; the risk of changes in governmental regulations or enforcement practices; and other important factors that could cause actual results to differ materially from those projected. All such factors are difficult to predict and are beyond Kindly MD's and Nakamoto's control, including those detailed in Kindly MD's Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and such other documents of Kindly MD filed, or to be filed, with the SEC that are or will be available on Kindly MD's website at www.kindlymd.com and on the website of the SEC at www.sec.gov. All forward-looking statements are based on assumptions that Kindly MD and Nakamoto believe to be reasonable but that may not prove to be accurate. Any forward-looking statement speaks only as of the date on which such statement is made, and neither Kindly MD or Nakamoto undertakes any obligation to correct or update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by applicable law. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250617636586/en/

    Media Contacts

    Carissa Felger/Sam Cohen

    Gasthalter & Co.

    (212) 257-4170

    [email protected]

    For KindlyMD:

    Valter Pinto, Managing Director

    KCSA Strategic Communications

    (212) 896-1254

    [email protected]

    Get the next $NAKA alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $NAKA
    $UPXI

    CompanyDatePrice TargetRatingAnalyst
    Upexi Inc.
    $UPXI
    6/16/2025$16.00Neutral → Overweight
    Cantor Fitzgerald
    More analyst ratings

    $NAKA
    $UPXI
    Leadership Updates

    Live Leadership Updates

    See more
    • Nakamoto Holdings Appoints Andrew Creighton as Chief Commercial Officer to Lead Global Bitcoin Growth Strategy

      Nakamoto Holdings Inc. ("Nakamoto"), a Bitcoin-native holding company, which previously announced its anticipated merger with Kindly MD, Inc. (NASDAQ:NAKA) ("KindlyMD"), today announced the appointment of Andrew Creighton as Chief Commercial Officer. In this role, Andrew will lead Nakamoto's commercial strategy across global markets, including overseeing licensing, partnerships, capital formation, and regional expansion. Andrew is a seasoned operator with deep expertise in scaling international businesses, raising institutional capital, and securing transformational partnerships. He currently serves as Chief Commercial Officer of BTC Inc, publisher of Bitcoin Magazine and host of the annu

      6/25/25 9:00:00 AM ET
      $NAKA
      Medical/Nursing Services
      Health Care
    • Nakamoto Holdings Appoints Tyler Evans as Chief Investment Officer to Lead Bitcoin-Native Capital Deployment

      Nakamoto Holdings Inc. ("Nakamoto"), a Bitcoin-native holding company, which previously announced its anticipated merger with Kindly MD, Inc. (NASDAQ:NAKA) ("KindlyMD"), today announced the appointment of Tyler Evans as Chief Investment Officer. Building on his six-year track record at UTXO Management, Tyler will lead the strategy and execution of Nakamoto's Bitcoin reserve deployment by originating and structuring deals across capital markets to grow the company's balance sheet and drive long-term shareholder value. Tyler brings over a decade of experience building Bitcoin-native financial infrastructure. He is a Co-Founder and Chief Investment Officer of UTXO Management, a thesis-driven

      6/18/25 9:18:00 AM ET
      $NAKA
      Medical/Nursing Services
      Health Care

    $NAKA
    $UPXI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Marshall Allan bought $1,500,001 worth of shares (657,895 units at $2.28) and was granted 75,000 shares, increasing direct ownership by 484% to 884,318 units (SEC Form 4)

      4 - UPEXI, INC. (0001775194) (Issuer)

      4/25/25 4:01:36 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Chief Financial Officer Norstrud Andrew James bought $100,001 worth of shares (43,860 units at $2.28) and was granted 100,000 shares, increasing direct ownership by 942% to 159,138 units (SEC Form 4)

      4 - UPEXI, INC. (0001775194) (Issuer)

      4/25/25 4:01:26 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Salkind Gene bought $550,002 worth of shares (241,229 units at $2.28), increasing direct ownership by 195% to 365,127 units (SEC Form 4)

      4 - UPEXI, INC. (0001775194) (Issuer)

      4/25/25 4:01:17 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care

    $NAKA
    $UPXI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Upexi, Inc. upgraded by Cantor Fitzgerald with a new price target

      Cantor Fitzgerald upgraded Upexi, Inc. from Neutral to Overweight and set a new price target of $16.00

      6/16/25 7:42:40 AM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care

    $NAKA
    $UPXI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Upexi Announces Intent to List SEC-Registered Shares On-Chain via Superstate's Opening Bell

      TAMPA, Fla., June 26, 2025 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a brand owner specializing in the development, manufacturing, and distribution of consumer products with diversification into the cryptocurrency space, today announced its intention to tokenize its SEC-registered shares using Opening Bell, an on-chain issuance platform from financial technology firm Superstate. Opening Bell enables companies to tokenize public equity via blockchain infrastructure, making shares tradable on-chain. This announcement expands upon Upexi's existing Nasdaq listing and upon official listing may introduce key investor benefits, including: 24/7 trading and

      6/26/25 8:00:00 AM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Nakamoto Holdings Appoints Andrew Creighton as Chief Commercial Officer to Lead Global Bitcoin Growth Strategy

      Nakamoto Holdings Inc. ("Nakamoto"), a Bitcoin-native holding company, which previously announced its anticipated merger with Kindly MD, Inc. (NASDAQ:NAKA) ("KindlyMD"), today announced the appointment of Andrew Creighton as Chief Commercial Officer. In this role, Andrew will lead Nakamoto's commercial strategy across global markets, including overseeing licensing, partnerships, capital formation, and regional expansion. Andrew is a seasoned operator with deep expertise in scaling international businesses, raising institutional capital, and securing transformational partnerships. He currently serves as Chief Commercial Officer of BTC Inc, publisher of Bitcoin Magazine and host of the annu

      6/25/25 9:00:00 AM ET
      $NAKA
      Medical/Nursing Services
      Health Care
    • KindlyMD and Nakamoto Announce an Additional $51.5 Million In PIPE Financing To Support Bitcoin Treasury Efforts

      Kindly MD, Inc. (NASDAQ:NAKA) ("KindlyMD"), which previously announced its anticipated merger with Nakamoto Holdings Inc. ("Nakamoto"), a Bitcoin-native holding company, today announced the close of an additional $51.5 million in private placement in public equity ("PIPE financing") to support its efforts to establish a Bitcoin treasury. To date, KindlyMD has raised a total of approximately $563 million in PIPE financing and $763 million including convertible notes. "Investor demand for Nakamoto is incredibly strong. This additional financing was raised in under 72 hours, adding the option for more working capital in addition to acquiring bitcoin," said David Bailey, Founder and CEO of Na

      6/20/25 9:24:00 AM ET
      $NAKA
      Medical/Nursing Services
      Health Care

    $NAKA
    $UPXI
    SEC Filings

    See more
    • Upexi Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - UPEXI, INC. (0001775194) (Filer)

      6/26/25 5:00:22 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form D filed by Kindly MD Inc.

      D - Kindly MD, Inc. (0001946573) (Filer)

      6/26/25 6:01:43 AM ET
      $NAKA
      Medical/Nursing Services
      Health Care
    • Kindly MD Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Kindly MD, Inc. (0001946573) (Filer)

      6/25/25 9:10:08 AM ET
      $NAKA
      Medical/Nursing Services
      Health Care

    $NAKA
    $UPXI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Rudick Brian Benjamin claimed ownership of 438,597 shares (SEC Form 3)

      3 - UPEXI, INC. (0001775194) (Issuer)

      6/3/25 6:04:17 AM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Chief Executive Officer Marshall Allan bought $1,500,001 worth of shares (657,895 units at $2.28) and was granted 75,000 shares, increasing direct ownership by 484% to 884,318 units (SEC Form 4)

      4 - UPEXI, INC. (0001775194) (Issuer)

      4/25/25 4:01:36 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 4 filed by Director Williams Thomas Charles

      4 - UPEXI, INC. (0001775194) (Issuer)

      4/25/25 4:01:45 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care

    $NAKA
    $UPXI
    Financials

    Live finance-specific insights

    See more
    • Upexi Regains Compliance with NASDAQ

      Filing Form 10-K for the Year Ended June 30, 2024Filing Form 10-Q for the Quarter Ending September 30, 2024 TAMPA, FL / ACCESSWIRE / December 23, 2024 / Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a brand owner specializing in the development, manufacturing and distribution of consumer products, announced its financial results for the year ended June 30, 2024 and the first quarter ending September 30, 2024 last week. On November 20, 2024 the Company received written notice (the "Compliance Notice") from Nasdaq informing the Company that it has regained compliance with Nasdaq Listing Rule 5250( c)(1) (the "Rule"). The Staff had concluded that with the filing of these two periodic re

      12/23/24 9:00:00 AM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Upexi Reports Fiscal Second Quarter 2024 Financial Results

      TAMPA, FL / ACCESSWIRE / February 14, 2024 / Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a multi-faceted Amazon and Direct to Consumer brand owner and innovator in aggregation, today reported its financial results for the fiscal second quarter 2024 ending December 31, 2023."During the quarter we continued to focus on optimizing and streamlining our operations, investing in our higher margin Brand Products and generating positive Adjusted EBITDA. While revenue for the most recent fiscal second quarter decreased sequentially, the operating measures we took allowed us to increase gross profit margins to 38%, as compared to the prior fiscal first quarter of 31.8%. We also generated pos

      2/14/24 4:05:00 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Upexi to Host Fiscal 2024 Second Quarter Financial Results Conference Call on February 14th at 4:30 PM ET

      TAMPA, FL / ACCESSWIRE / February 12, 2024 / Upexi Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a multi-faceted Amazon and Direct-to-Consumer brand owner and innovator in aggregation, today announced it will host a conference call on Wednesday, February 14, 2024 at 4:30 p.m. ET, to discuss its financial results for the fiscal 2024 second quarter and provide a business update.Financial Results Conference CallEvent:Fiscal 2024 Second Quarter Financial Results Conference CallDate:Wednesday, February 14, 2024Time:4:30 p.m. Eastern TimeLive Call:1-877-407-9716 (U.S. Toll Free) or 1-201-493-6779 (International)Webcast:https://ir.upexi.com/news-events/ir-calendarFor those unable to join the confe

      2/12/24 9:00:00 AM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care

    $NAKA
    $UPXI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Upexi Inc.

      SC 13G - UPEXI, INC. (0001775194) (Subject)

      5/31/23 7:05:10 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G filed by Upexi Inc.

      SC 13G - UPEXI, INC. (0001775194) (Subject)

      3/10/23 4:37:37 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Upexi Inc. (Amendment)

      SC 13G/A - UPEXI, INC. (0001775194) (Subject)

      3/10/23 4:36:56 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care